Clinical Trials Logo

Clinical Trial Summary

This Phase 2 study will evaluate the safety and efficacy of monthly intravenous doses of IXT-m200 in treatment-seeking individuals with methamphetamine (METH) use disorder. The hypothesis is that treatment with IXT-m200 will reduce the occurrence of stimulant-positive samples compared to placebo (following an initial grace period during which relapses may occur).


Clinical Trial Description

n/a


Study Design


Related Conditions & MeSH terms


NCT number NCT05034874
Study type Interventional
Source InterveXion Therapeutics, LLC
Contact Misty Stevens
Phone 5015542377
Email [email protected]
Status Not yet recruiting
Phase Phase 2
Start date April 1, 2022
Completion date December 20, 2023

See also
  Status Clinical Trial Phase
Completed NCT03226223 - Pharmacogenetics of Naltrexone for Stimulant Abuse Phase 2
Completed NCT02907853 - Contingency Management for Meth in South Africa Methamphetamine Abuse in South Africa N/A
Recruiting NCT04616625 - Cardiovascular Effects of Prenatal Methamphetamine Exposure
Recruiting NCT04061941 - Change in Cognitive Function in Stimulant Users
Completed NCT01967381 - Targeting GABA and Opioid Systems for a Pharmacotherapy for Methamphetamine Abuse Early Phase 1
Terminated NCT01019707 - Safety Assessment of Atomoxetine With MA IV Administration Phase 1
Completed NCT01011829 - Varenicline vs Placebo for the Treatment of Methamphetamine Dependence Phase 2
Recruiting NCT04706624 - Screen, Treat and Retain Meth-using People With Opioid Use Disorders at Methadone Clinics N/A
Recruiting NCT04109014 - FASTLANE II: Reducing Sex, Drug, and Mental Health Risk N/A
Completed NCT03336866 - Study of Antibody for Methamphetamine Outpatient Therapy Phase 1/Phase 2
Completed NCT01822132 - Risky Decision Making in Methamphetamine Users: The Role of Opioid Blockade N/A
Active, not recruiting NCT01062451 - An ACE Inhibitor (Perindopril) or an Angiotensin Receptor Blocker (Candesartan) as a Treatment for Methamphetamine Dependence Phase 1
Completed NCT01063205 - NAC as a Potential Treatment for Methamphetamine Dependence Phase 1
Enrolling by invitation NCT03709667 - Exercise in Methamphetamine Use Disorder Upregulation and Neural Function Early Phase 1
Recruiting NCT04544124 - Delivering Contingency Management in Outpatient Addiction Treatment N/A
Completed NCT01073319 - Rivastigmine as a Treatment for Methamphetamine Dependence Phase 1
Recruiting NCT03884946 - The Getting Off App for Methamphetamine-Using Gay and Bisexual Men N/A
Completed NCT02008526 - Theory-based Text Messaging to Reduce Methamphetamine Use and HIV Risks Among MSM N/A
Completed NCT01571167 - Varenicline as a Treatment for Methamphetamine Dependence Phase 1
Not yet recruiting NCT01273701 - Combination of Psychosocial Intervention and Slow Prosecutions for the Treatment of Methamphetamine Abuse/Dependence N/A